Chronic liver disease affects over one third of Americans and over one billion people worldwide. The annual cost associated with healthcare for these individuals exceeds $20 billion in the US alone. The most common etiologies are nonalcoholic fatty liver disease (NAFLD), alcoholic liver disease, and chronic hepatitis B and C infections. Each of these is characterized by chronic hepatocellular damage, which in turn can lead to chronic inflammation, fibrosis, cirrhosis, and hepatocellular carcinoma. Although these causes of chronic liver disease all are very different, recent work by others and us suggests that each results in abnormalities in certain overlapping signaling pathways that, in part, mediate hepatocellular damage and the subsequent response to injury. The broad working hypothesis of this program project is that hepatocellular damage of varying etiologies, such as non-alcoholic fatty liver, alcohol, and other toxins, each leads to the development of chronic liver disease as a consequence of disrupting multiple overlapping pathways. The goal of this program project will be to understand collectively how these distinct signaling pathways within the hepatocyte integrate in order to drive the development of chronic liver disease. This hypothesis is conceptually novel and will be highly transformative to the field of hepatology in a manner that will stimulate new ways to fundamentally re-assess how certain liver diseases are understood and treated. This hypothesis will be tested through four individual research projects. Project 1 will test whether chronic inflammation and liver injury increases expression of the type 3 isoform of the inositol 1,4,5-trisphosphate receptor (InsP3R-3) in hepatocytes, and whether expression of this particular intracellular Ca2+ channel in turn is responsible for the impaired liver regeneration that occurs in chronic liver disease/cirrhosis. Project 2 will investigate which of th three isoforms of the InsP3R are in the mitochondrial-associated membranes (MAMs) of hepatocytes and how the different channel isoforms regulate mitochondrial and ER function. Project 3 will test how the stress-responsive MAP kinase phosphatase-1 (MKP- 1) is involved in the development of chronic hepatic inflammation and liver injury/repair and whether MKP-1 serves as central node to coordinate signals that promote liver repair. Project 4 will determine how O-GlcNAc transferase (OGT) transduces toxic insults into hepatocyte survival/death signaling, and how OGT deficiency contributes to the development of chronic liver disease. To help carry out these projects, core facilities will be established for molecular, cell and animal models, cell and tissue imaging, translational studies, and administration. These four projects will collectively provide a comprehensive investigation of how major signal transduction pathways in hepatocytes integrate to regulate the balance between growth and metabolism in liver health and disease. The results of these studies will have broad clinical implications for understanding the response to injury in a range of chronic liver diseases, including non-alcoholic fatty liver disease, liver disease resulting from exposure to alcohol and other hepatotoxins, and chronic viral hepatitis.

Public Health Relevance

Chronic liver disease affects over one third of Americans and over one billion people worldwide. This Program Project Grant will collectively provide a comprehensive investigation of how major signaling pathways in hepatocytes integrate to regulate the balance between growth and metabolism in liver health and disease. The results of these studies will have broad clinical implications for understanding the response to injury in a range of chronic liver diseases, including non-alcoholic fatty liver disease, liver disease resulting from exposure to alcohol and other hepatotoxins, and chronic viral hepatitis.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Research Program Projects (P01)
Project #
5P01DK057751-19
Application #
9698930
Study Section
Special Emphasis Panel (ZDK1)
Program Officer
Burgess-Beusse, Bonnie L
Project Start
2000-04-01
Project End
2021-04-30
Budget Start
2019-05-01
Budget End
2020-04-30
Support Year
19
Fiscal Year
2019
Total Cost
Indirect Cost
Name
Yale University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
043207562
City
New Haven
State
CT
Country
United States
Zip Code
06520
Qian, Kevin; Wang, Simeng; Fu, Minnie et al. (2018) Transcriptional regulation of O-GlcNAc homeostasis is disrupted in pancreatic cancer. J Biol Chem 293:13989-14000
Boeckel, Göran R; Ehrlich, Barbara E (2018) NCS-1 is a regulator of calcium signaling in health and disease. Biochim Biophys Acta Mol Cell Res :
Lawan, Ahmed; Min, Kisuk; Zhang, Lei et al. (2018) Skeletal Muscle-Specific Deletion of MKP-1 Reveals a p38 MAPK/JNK/Akt Signaling Node That Regulates Obesity-Induced Insulin Resistance. Diabetes 67:624-635
Franca, Andressa; Filho, Antonio Carlos Melo Lima; Guerra, Mateus T et al. (2018) Effects of endotoxin on type 3 inositol 1,4,5-trisphosphate receptor in human cholangiocytes. Hepatology :
Lemos, Fernanda O; Ehrlich, Barbara E (2018) Polycystin and calcium signaling in cell death and survival. Cell Calcium 69:37-45
Yang, Xiaoyong; Qian, Kevin (2017) Protein O-GlcNAcylation: emerging mechanisms and functions. Nat Rev Mol Cell Biol 18:452-465
Giehl, Esther; Lemos, Fernanda O; Huang, Yan et al. (2017) Polycystin 2-dependent cardio-protective mechanisms revealed by cardiac stress. Pflugers Arch 469:1507-1517
Feriod, Colleen N; Oliveira, Andre Gustavo; Guerra, Mateus T et al. (2017) Hepatic Inositol 1,4,5 Trisphosphate Receptor Type 1 Mediates Fatty Liver. Hepatol Commun 1:23-35
Kruglov, Emma; Ananthanarayanan, Meenakshisundaram; Sousa, Pedro et al. (2017) Type 2 inositol trisphosphate receptor gene expression in hepatocytes is regulated by cyclic AMP. Biochem Biophys Res Commun 486:659-664
Lawan, Ahmed; Bennett, Anton M (2017) Mitogen-Activated Protein Kinase Regulation in Hepatic Metabolism. Trends Endocrinol Metab 28:868-878

Showing the most recent 10 out of 113 publications